MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC). Still, many patients do not respond to these inhibitors. PD‐L1 (CD274) expression, one of the factors th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Pathol
Main Authors: Stutvoet, Thijs S, Kol, Arjan, de Vries, Elisabeth GE, de Bruyn, Marco, Fehrmann, Rudolf SN, Terwisscha van Scheltinga, Anton GT, de Jong, Steven
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Ltd 2019
Assuntos:
Original Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767771/
https://ncbi.nlm.nih.gov/pubmed/30972766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/path.5280
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares